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1. Introduction
Hyperbaric oxygen treatment (HBO
2
) is a widely accepted adjuvant therapy in various health 
conditions that exhibit impaired tissue blood flow. The list of indications is widening as 
our knowledge and understanding on the mechanisms of HBO
2
 action is getting larger. For 
example, in August 2013, the US Food and Drug Administration declared artery occlusion as 
one of the 13 specific indications for HBO therapy [1].
In April 2016, the Tenth European Consensus Conference on Hyperbaric Medicine was held, 
bringing consensus on accepted and non-accepted clinical indications and practice of hyper-
baric oxygen treatment. Recommendations are listed in three levels of indications: from Type 
1—strongly suggest that HBO
2
 is to be accepted as primary treatment (example of accepted 
indications: carbon monoxide (CO) poisoning, mandibular osteonecrosis, gas embolism, 
anaerobic or mixed infections, decompression sickness, sudden deafness, etc.); Type 2—HBO
2
 
is suggested as it is supported by evidences (suggested indications: diabetic foot lesions, fem-
oral head fracture, ischemic ulcers, etc.) and Type 3—where HBO
2
 is optional, since it is not 
fully supported by evidences (e.g. brain injuries, radio-induced lesions, post-vascular proce-
dure reperfusion syndrome, etc.). This consensus also provided negative recommendations, 
for example, where HBO
2
 should not be used, such as autism spectrum disorders, placental 
insufficiency and cerebral palsy, to list some of them [2].
At high pressures, the delivery of the dissolved oxygen in plasma is enhanced, which con-
tributes to better tissue oxygenation, cellular metabolism and, ultimately, healing. However, 
this is not the only potential mechanism for improved outcome of many diseases treated 
with HBO
2
, since oxygen is highly reactive molecule and can induce upregulation of many 
various enzymatic systems in the cell, at cellular, genetic and molecular level. Particularly, 
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vascular/endothelial function is affected by the HBO
2
. Our understanding of these mecha-
nisms of the HBO
2
 effects is still emerging. There have been many controversies related to the 
HBO
2
 protocols and indications. It is known that, as well as HBO
2
 exhibit beneficiary effects 
on the tissue perfusion, it demonstrates high toxicity at higher pressures, due to increased 
oxidative stress and barotrauma. On the other hand, there is still a lack of the translation of 
the knowledge on the mechanisms of action of HBO
2
 obtained from the experimental research 
to the clinical practice.
2. Effects of HBO
2
 in brain injury
One interesting field of research of use of HBO
2
 in treatment is brain injury, particularly 
traumatic brain injury and stroke in diabetes. In prospective, randomized controlled trial, in 
79 diabetes patients suffering from acute intracerebral hemorrhagic stroke, both short-term 
and long-term neurological consequences were studied and compared in group on normo-
baric oxygen therapy and on HBO
2
. At 1-month follow-up period, no distinct difference was 
observed between each group. However, after 6 months of follow-up, HBO
2
 group exhib-
ited better neurological consequences compared to control group (Barthel Index: 85.1 versus 
65.6%, P = 0.080; mRS: 89.4 versus 68.8%, P = 0.045; Glasgow outcome scale: 83.0 versus 62.5%, 
P = 0.073; National Institute of Stroke Scale (NIHSS): 80.9 versus 56.2%, P = 0.035), supporting 
the hypothesis that HBO
2
 is safe and effective therapy for the long-term neurological out-
comes in diabetic patients with hemorrhagic stroke [3].
In traumatic brain injury (TBI) clinical study, 28 patients with persistent cognitive impairment 
caused by mild-to-moderate TBI were included and examined for the stem cell mobilization 
and recruitment to repair damaged neuronal tissue. HBO₂ treatment correlated with stem 
cell mobilization as well as increased cognitive performance. The limitation of the study was 
that peripheral blood sample was tested [4]. Similarly, 50 randomized subjects with TBI were 
examined for cognition and post-traumatic stress disorder symptoms. They completed a total 
of 30 HBO
2
 exposures compared to sham-treated group. The symptoms improved in both 
groups and there were no statistically significant differences between groups. However, there 
was some improvement in the treatment group versus the control after subgroup analyses 
based on concussion history and individual test components [5]. In randomized controlled 
clinical trial, normobaric oxygen therapy was also employed in the treatment of 52 patients 
with either ischemic or hemorrhagic stroke in the first 12 h of accident. Normobaric oxy-
genation could improve long-time outcome of the patients based on the modified Rankin 
Scale neurology disability scoring system, but not on the Barthel results, 6 months after the 
discharge from hospital [6]. The retrospective observational trial demonstrated significant 
improvement in patients with acute neurological deficits due to ischemic stroke following 
cardiac surgery treated with HBO
2
. However, the last study lacks control, which weakens the 
level of evidence of conclusions [7].
Contrary to this beneficiary results, recent Cochrane database systemic review included 11 
randomized clinical trials (RCTs) involving 705 participants to examine the effect of HBO
2
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on clinical outcomes of ischemic stroke. Fatality rate at 6 months was not significantly differ-
ent in those receiving HBO
2
 compared with the control group. However, HBO
2
 significantly 
improved 4 of 14 scale measures of disability and functional performance, for example, the 
mean Orgogozo Scale score was higher (MD 27.9 points, 95% CI 4.0–51.8, P value 0.02) and 
Trouillas Disability Scale score was lower with HBO
2
 (mean difference (MD) 2.2 point reduc-
tion with HBOT, 95% CI 0.15–4.3, P value 0.04). The limiting factor of this meta-analysis was 
variable quality of the methodology of the evaluated trials; thus, it is not conclusive on clear 
clinical benefit as well as on exclusion of it [8].
Analyses of several trials, such as the Department of Defense/Veterans Administration 
(DoD/VA) sponsored trials, previous published reports on the use of HBO
2
 therapy on 
stroke and moderate chronic traumatic brain injury (mTBI) and preliminary reports from 
the HOPPS Army trial, suggest the approval of HBO
2
 for neurological indications, especially 
for mTBI and post-concussion syndrome (PCS), as a safe and viable treatment for recovery 
in the post-acute phase [9]. In the context of the preparation of impending National Institute 
of Neurologic Disorders and Stroke-funded, multi-center, randomized, adaptive Phase II 
clinical trial—the Hyperbaric Oxygen Brain Injury Treatment (HOBIT) trial, 30 studies (8 
clinical and 22 pre-clinical) that administered HBO
2
 within 30 days of a TBI were analyzed. 
The pre-clinical studies consistently reported positive treatment effects across a variety of 
outcome measures with almost no safety concerns. Of the eight clinical studies reviewed, 
four were based on the senior author’s (GR) investigation of HBO
2
 as a treatment for acute 
severe TBI [10].
The mechanisms by which HBO
2
 induces brain neuroplasticity can be demonstrated by highly 
sensitive MRI techniques of dynamic susceptibility contrast-enhanced (DSC) and diffusion 
tensor imaging (DTI). Fifteen patients afflicted with prolonged post-concussion syndrome 
were treated with 60 daily HBO
2
 sessions. The cerebral blood flow and volume significantly 
increased after HBO
2
. There was significant improvement in the memory, information pro-
cessing speed, executive functions and global cognitive scores (evaluated by NeuroTrax) after 
HBO
2
. Fractional anisotropy values were significantly increased and mean diffusivity was 
significantly decreased in both white and gray matter structures after HBO
2
 [11].
Hyperbaric oxygen in combination with thrombolysis shows neuroprotection in acute isch-
emic stroke in rats by reducing infarct volume and improving functional outcome in the early 
post-stroke period [12]. HBO
2
 can induce cerebral angiogenesis and improve both white and 
gray microstructures indicating regeneration of nerve fibers which correlates with the neuro-
cognitive improvements [11]. Potential metabolic effects in the mechanisms of HBO
2
-induced 
improved neurostructural and neurofunctional outcomes were also examined in diabetic 
female rats. Particular emphasis was given to the role of cyp450 enzymes’ metabolites of 
arachidonic acid. Cortical infarct size and total infarct size were equally and significantly 
reduced in HBO
2
- and HET0016 (inhibitor of 20-HETE production)-treated diabetic female 
rats. Cyp2J3 mRNA was significantly increased in all study groups, and Cyp2C11 mRNA was 
significantly increased in the group receiving HET0016 treatment followed by HBO
2
 expo-
sure and in the multiple HBO
2
 group compared to the control group. Endothelial nitric oxide 
synthase (eNOS) enzyme’s expression was significantly increased after HBO
2
 treatments, and 
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expression of epoxide hydrolase 2 was increased in all groups compared to the control group. 
All together, these results suggested that cytochrome P450 metabolites and the NO pathway 
are involved in the observed therapeutic effects of HBO
2
 and HET0016 in diabetic female 
Sprague-Dawley rats. Furthermore, HBO
2
 and HET0016 are very effective treatments of 
stroke [13]. Similarly, HBO
2
 treatment on rats with experimental traumatic spinal cord injury 
was performed 1, 6 and 24 h after brain trauma. HBO
2
 improved the results of the inclined 
plane level tests and motor strength test. Early HBO
2
 treatment resulted in higher recovery 
rates, particularly when treatment started in the first hour. In traumatized rats, nitrite levels 
in spinal cord increased compared to control group; however, they diminished after HBO
2
 
treatments. As earlier the HBO
2
 treatment was conducted, the greater decrease in nitrite levels 
was observed [14].
The safety of more advanced attempts to deliver increased oxygen levels to hypoxic or isch-
emic tissues, such as with hyperbaric oxygen therapy, is also being questioned [15]. There are 
substantial number of evidence that HBO
2
 significantly improves physiologic measures with-
out causing cerebral or pulmonary toxicity and can potentially improve clinical outcome [10]. 
In contrast to chronic, intermittent HBO
2
 treatments which do not increase oxidative stress 
and restore the mechanisms of vascular relaxation in diabetic rats [16, 17], acute HBO
2
 can 
increase oxidative stress and transiently impair the endothelium-dependent vasorelaxation, 
even in healthy rats [18]. In study on isolated aortic rings in healthy male Sprague-Dawley 
rats, acetylcholine-induced relaxation and hypoxia-induced relaxation which were impaired 
after acute HBO
2
 due to increased serum oxidative stress and superoxide production were 
restored by superoxide scavenger TEMPOL. The mRNA expression of iNOS was decreased 
in the acute HBO
2
 and 24 h after HBO
2
 while gene expression of superoxide dismutase SOD1 
and SOD3 and NADPH oxidase was increased in the intermittent HBO
2
 group. The expres-
sion and activity of catalase and glutathione peroxidase were increased in the intermittent 
HBO
2
 group as well. Vasorelaxation was restored and oxidative stress was normalized 24 h 
after the treatment [18].
In attempt to evaluate possibility to use HBO
2
 in other neurological diseases, such as 
Alzheimer’s disease (AD), the studies were performed in the triple transgenic model of AD 
in old mice. HBO
2
 reduced hypoxia, amyloid burden and tau phosphorylation in 3xTg mice 
and ameliorated their behavioral deficits. HBO
2
 attenuated neuroinflammatory processes by 
reducing astrogliosis, microgliosis and the secretion of proinflammatory cytokines (IL-1β and 
TNFα) and increasing expression of scavenger receptor A, arginase1 and anti-inflammatory 
cytokines (IL-4 and IL-10) [19]. The beneficial effect of HBO
2
 for neurological outcome after 
stroke has been illustrated in many studies, and meanwhile, many underlying mechanisms 
associated with neuroprotection have been demonstrated, such as cerebral oxygenation pro-
motion and metabolic improvement, decreased oxidative stress and apoptosis, blood-brain 
barrier protection, anti-inflammation and decrease in cerebral edema, intracranial pres-
sure modulation and increased vascular and neural regeneration [20]. However, as noted 
previously, studies performed in human stroke patients lack controls. Thus, data are not 
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sufficiently evidence-based, although promising. In human stroke, there is an urgent need 
for the randomized double-blind controlled clinical trials to have undoubted evidence on the 
HBO
2
 effects in stroke. In the future, this type of studies will lead to uniform criteria on the 
dose, number of sessions and oxygenation levels in different types of stroke.
3. Potential HBO
2
 use in inflammatory bowel diseases
Another interesting and controversial field of potential HBO
2
 application is inflammatory 
bowel diseases and radiation-induced chronic gastrointestinal symptoms. Again, some stud-
ies presented beneficiary effects of HBO
2
 in the model of ulcerative colitis, by stimulating 
colonic stem cells to promote healing. However, this study lack control group [21]. On the 
other hand, well-controlled study in mice model of DSS-induced colitis demonstrated that 
HBO
2
 significantly reduces colitis severity. Gene expression and activity of antioxidative 
enzymes were changed by the HBO
2
, as well as the inflammatory microenvironment in the 
gut mucosa. This was manifested by the clinical features of colitis (e.g. bleeding, frequency 
of stool) and by histological assessment of the gut tissue and reversal of IL-1β, IL-2 and IL-6 
gene expression. Also, the immune cell expansion and mobilization were impaired. HIF-1α 
mRNA level strongly correlated to GPx1, SOD1 and IL-6 mRNA expression, suggesting that 
HIF-1α is involved in the transcriptional regulation of these genes during colonic inflamma-
tion and HBO
2
 [22]. On the other hand, a prospective randomized study failed to demonstrate 
that HBO
2
 can improve the effects of standardized treatment in a severe attack of ulcerative 
colitis [23]. Additionally, no evidence that patients with radiation-induced chronic gastro-
intestinal symptoms, including those patients with rectal bleeding, benefit from hyperbaric 
oxygen therapy in HOT2 study (a double-blind, sham-controlled, phase 3 randomized study 
of patients (≥18 years) with chronic gastrointestinal symptoms for 12 months or more after 
radiotherapy) [24]. Obviously, there is a discrepancy of the data from experimental study 
and clinical observational studies, which need to be resolved by well-controlled randomized 




 is an established therapeutic approach in many acute, life-threatening conditions and 
also has been submitted to scrutinizing evaluation for new indications. Not only there is a 
wide field of potential application of HBO
2
 in experimental research and clinical therapy, 





-induced beneficiary effects are under intense investigation and their 
understanding promise HBO
2
 with low unwanted side effects when utilized in well-designed 
controlled fashion.
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